AU2013221230A1 - Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients - Google Patents

Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients Download PDF

Info

Publication number
AU2013221230A1
AU2013221230A1 AU2013221230A AU2013221230A AU2013221230A1 AU 2013221230 A1 AU2013221230 A1 AU 2013221230A1 AU 2013221230 A AU2013221230 A AU 2013221230A AU 2013221230 A AU2013221230 A AU 2013221230A AU 2013221230 A1 AU2013221230 A1 AU 2013221230A1
Authority
AU
Australia
Prior art keywords
patient
viral
infection
sialidase
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013221230A
Other languages
English (en)
Inventor
Tiejun Li
Ron Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of AU2013221230A1 publication Critical patent/AU2013221230A1/en
Priority to AU2017258955A priority Critical patent/AU2017258955A1/en
Priority to AU2019226190A priority patent/AU2019226190B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013221230A 2012-02-17 2013-02-19 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients Abandoned AU2013221230A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017258955A AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2019226190A AU2019226190B2 (en) 2012-02-17 2019-09-05 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US61/600,545 2012-02-17
US201261727627P 2012-11-16 2012-11-16
US61/727,627 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017258955A Division AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients

Publications (1)

Publication Number Publication Date
AU2013221230A1 true AU2013221230A1 (en) 2014-10-02

Family

ID=48984833

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013221230A Abandoned AU2013221230A1 (en) 2012-02-17 2013-02-19 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2017258955A Abandoned AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2019226190A Ceased AU2019226190B2 (en) 2012-02-17 2019-09-05 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017258955A Abandoned AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2019226190A Ceased AU2019226190B2 (en) 2012-02-17 2019-09-05 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Country Status (9)

Country Link
US (5) US20130280332A1 (enExample)
EP (1) EP2841092B1 (enExample)
JP (1) JP2015508780A (enExample)
CN (2) CN104203267A (enExample)
AU (3) AU2013221230A1 (enExample)
CA (1) CA2864746A1 (enExample)
ES (1) ES2970401T3 (enExample)
IL (2) IL234116B (enExample)
WO (1) WO2013123521A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
KR20170081213A (ko) 2014-11-06 2017-07-11 다나-파버 캔서 인스티튜트 인크. Ezh2 억제제 및 그의 용도
CA2966336A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20180177852A1 (en) * 2015-06-08 2018-06-28 Ansun Biopharma, Inc. Treatment of human metapneumovirus
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
EP4065139A1 (en) * 2019-11-25 2022-10-05 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
JP4933046B2 (ja) * 2002-09-06 2012-05-16 フィリップ モーリス ユーエスエー インコーポレイテッド 液体エアロゾル製剤、エアロゾル発生装置およびエアロゾル発生方法
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
KR20150001844A (ko) * 2006-01-24 2015-01-06 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
CA2780193A1 (en) * 2009-11-06 2011-05-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract

Also Published As

Publication number Publication date
ES2970401T3 (es) 2024-05-28
EP2841092C0 (en) 2023-12-06
US20210046165A1 (en) 2021-02-18
AU2019226190A1 (en) 2019-09-26
IL273194B2 (en) 2023-02-01
IL234116B (en) 2020-03-31
CN104203267A (zh) 2014-12-10
IL273194B (en) 2022-10-01
EP2841092A1 (en) 2015-03-04
EP2841092A4 (en) 2015-09-16
WO2013123521A1 (en) 2013-08-22
US20130280332A1 (en) 2013-10-24
US20170151315A1 (en) 2017-06-01
CN109529026A (zh) 2019-03-29
CA2864746A1 (en) 2013-08-22
US20250387457A1 (en) 2025-12-25
AU2019226190B2 (en) 2021-10-07
IL273194A (en) 2020-04-30
JP2015508780A (ja) 2015-03-23
AU2017258955A1 (en) 2017-12-14
EP2841092B1 (en) 2023-12-06
HK1207975A1 (en) 2016-02-19
US20150132274A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20220362272A1 (en) Medicament for prevention or treatment of rhinovirus infection
WO2021259195A1 (zh) 治疗新型冠状病毒肺炎的联合用药物
CN111346219A (zh) 干扰素在制备预防冠状病毒感染或预防冠状病毒感染引发的疾病的药物中的用途
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
Nomier et al. Distinctive Therapeutic Strategies against Corona Virus19 (COVID-19): A Pharmacological Review.
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
US20230149429A1 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
EP4149619A1 (en) Treatment of respiratory viral infections
CN108926707A (zh) Pf4的抗rsv应用
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
US20250186474A1 (en) Pharmaceutical solution composition and oral mist inhaler comprising the same
WO2023198757A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
MATICHESCU et al. COVID‑19: Main findings after a year and half of unease and the proper scientific progress
WO2024096743A1 (en) Sars-cov-2 binding antibody

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted